Latest News of CRNX
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
By Yahoo! Finance |
1 week ago
The NDC program offers advantages over ADCs by targeting GPCRs, allowing for selective internalization and intracellular cleavage....
We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth
By Yahoo! Finance |
3 months ago
Investors are attracted to unprofitable companies like Crinetics Pharmaceuticals despite risks. Analyzing its cash burn and runway, shareholders can assess its financial health and potential for growt...
Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
By Yahoo! Finance |
5 months ago
Crinetics Pharmaceuticals focuses on rare endocrine diseases and tumors. Shares were sold at $43.86 each, totaling $131,580, amid a $3.53 billion market cap. Insider Stephen Betz sold 24,000 shares in...